{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:54:09Z","timestamp":1787025249655,"version":"build-2736575974"},"reference-count":45,"publisher":"Oceanside Publications Inc.","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2021,3,1]]},"abstract":"<jats:p>Food allergies are common and affect 6\u20108% of children in the United States; they pose a significant burden on the quality of life of children with allergy and their caregivers due to multiple daily restrictions. Despite the recommended dietary avoidance, reactions tend to occur\n due to unintentional exposure to the allergenic food trigger. Fear of accidental ingestions with potentially severe reactions, including anaphylaxis and death, creates anxiety in individuals with food allergy. Oral immunotherapy has emerged as a form of active and potentially disease-modifying\n treatment for common food allergies encountered in childhood. The efficacy of oral immunotherapy is high, with the majority of participants achieving desensitization and, as a result, protection from trace exposures and improved quality of life. The main risk of oral immunotherapy consists\n of allergic reactions to treatment. In general, rates of allergic reactions and anaphylaxis are reported to be higher in individuals pursuing therapy options, but most subjects who undergo oral immunotherapy will likely experience mild or moderate reactions during treatment. Adverse events\n tend to reduce in both frequency and number in the maintenance period. The use of immune modulators alongside oral immunotherapy has been suggested, with the aim to improve efficacy and safety, and to facilitate the overall process. It is evident that the landscape of food allergy management\n is changing and that the future looks brighter, with different options emerging over time. The process of how to choose the appropriate option becomes a discussion between the clinician and the patient, which involves a joint review of the current medical evidence but also the patient's preference\n for balancing particular attributes of the treatment. By working together, providers and patients will ensure achievement of the best possible outcome for children with food allergies.<\/jats:p>","DOI":"10.2500\/aap.2021.42.200107","type":"journal-article","created":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T23:52:24Z","timestamp":1615247544000},"page":"118-123","source":"Crossref","is-referenced-by-count":22,"title":["Weighing the benefits and risks of oral immunotherapy in clinical practice"],"prefix":"10.2500","volume":"42","author":[{"given":"Aikaterini","family":"Anagnostou","sequence":"first","affiliation":[{"name":"From the Section of Pediatric Immunology, Allergy and Rheumatology, Baylor College of Medicine, Houston, Texas, and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1355","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1542\/peds.2011-0204","article-title":"The prevalence, severity, and distribution of childhood food allergy in the United States","volume":"128","author":"Gupta","year":"2011","journal-title":"Pediatrics"},{"key":"B2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaip.2014.06.008","article-title":"Clinical management of food allergy","volume":"3","author":"Bird","year":"2015","journal-title":"The J Alergy Clin Immunol Pract"},{"key":"B3","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1034\/j.1399-3038.2003.00072.x","article-title":"Assessment of quality of life in children with peanut allergy","volume":"14","author":"Avery","year":"2003","journal-title":"Pediatr Allergy Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/cea.12849"},{"key":"B5","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.anai.2014.06.027","article-title":"Food allergy quality of life","volume":"113","author":"Greenhawt","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B6","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jaip.2015.10.016","article-title":"Clinical management of psychosocial concerns related to food allergy","volume":"4","author":"Herbert","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B7","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.jaip.2014.05.001","article-title":"Longitudinal evaluation of food allergy-related bullying","volume":"2","author":"Annunziato","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B8","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.jaci.2012.02.001","article-title":"ICON: food allergy","volume":"129","author":"Burks","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"B9","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.anai.2020.01.008","article-title":"Food reactions during avoidance: focus on peanut","volume":"124","author":"Capucilli","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B10","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/cea.12751","article-title":"What do we mean by oral tolerance?","volume":"46","author":"Anagnostou","year":"2016","journal-title":"Clin Exp Allergy"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/children5040047"},{"key":"B12","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.jaci.2008.09.030","article-title":"A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow\u2019s milk allergy","volume":"122","author":"Skripak","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"B13","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJMoa1200435","article-title":"Oral immunotherapy for treatment of egg allergy in children","volume":"367","author":"Burks","year":"2012","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.jaci.2015.12.1316","article-title":"Long-term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy","volume":"137","author":"Jones","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B15","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.jaci.2010.12.1111","article-title":"A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response","volume":"127","author":"Varshney","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"B16","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/S0140-6736(13)62301-6","article-title":"Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial","volume":"383","author":"Anagnostou","year":"2014","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1056\/NEJMoa1812856","article-title":"AR101 oral immunotherapy for peanut allergy","volume":"379","author":"Vickery","year":"2018","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaci.2016.05.027","article-title":"Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective","volume":"139","author":"Vickery","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B19","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jaip.2020.07.009","article-title":"Five-year follow-up of early intervention peanut oral immunotherapy","volume":"9","author":"Lauren","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B20","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/j.jaci.2019.06.038","article-title":"Effect of sleep deprivation and exercise on reaction threshold in adults with peanut allergy: A randomized controlled study","volume":"144","author":"Shelley","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2017.05.006"},{"key":"B22","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jaip.2018.10.048","article-title":"Efficacy, safety, and quality of life in a multicenter, randomized, placebo-controlled trial of low-dose peanut oral immunotherapy in children with peanut allergy","volume":"7","author":"Blumchen","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B23","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jaip.2018.06.016","article-title":"Quality of life of food-allergic patients before, during, and after oral immunotherapy","volume":"7","author":"Epstein-Rigbi","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B24","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1710-1492-10-57","article-title":"Two year effects of food allergen immunotherapy on quality of life in caregivers of children with food allergies","volume":"10","author":"Arasi","year":"2014","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B25","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1710-1492-10-25","article-title":"Multiple-allergen oral immunotherapy improves quality of life in caregivers of food-allergic pediatric subjects","volume":"10","author":"Otani","year":"2014","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B26","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/S0140-6736(19)30420-9","article-title":"Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety","volume":"393","author":"Chu","year":"2019","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.jaci.2016.07.030","article-title":"Novel baseline predictors of adverse events during oral immunotherapy in children with peanut allergy","volume":"139","author":"Virkud","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B28","first-page":"CD009542","article-title":"Oral immunotherapy for milk allergy","volume":"11","author":"Yeung","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010638.pub2"},{"key":"B30","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1111\/j.1365-2222.2011.03699.x","article-title":"Efficacy and safety of high-dose peanut oral immunotherapy with factors predicting outcome","volume":"41","author":"Anagnostou","year":"2011","journal-title":"Clin Exp Allergy"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.06.038"},{"key":"B32","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.anai.2014.08.004","article-title":"Relation between eosinophilic esophagitis and oral immunotherapy for food allergy: a systematic review with meta-analysis","volume":"113","author":"Lucendo","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B33","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jaip.2019.07.034","article-title":"Risk factors and treatment outcomes for Oral Immunotherapy\u2013Induced Gastrointestinal Symptoms and Eosinophilic Responses (OITIGER)","volume":"8","author":"Goldberg","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B34","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1710-1492-10-7","article-title":"Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using omalizumab","volume":"10","author":"B\u00e9gin","year":"2014","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1710-1492-10-1","article-title":"Safety and feasibility of oral immunotherapy to multiple allergens for food allergy","volume":"10","author":"B\u00e9gin","year":"2014","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B36","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.anai.2019.08.463","article-title":"Oral immunotherapy for multiple foods in a pediatric allergy clinic setting","volume":"123","author":"Eapen","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B37","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S2468-1253(17)30392-8","article-title":"Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial","volume":"3","author":"Andorf","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B38","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jaci.2014.11.034","article-title":"Administration of a probiotic with peanut oral immunotherapy: a randomized trial","volume":"135","author":"Tang","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(17)30041-X"},{"key":"B40","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jaip.2019.09.004","article-title":"The role of shared decision making in pediatric food allergy management","volume":"8","author":"Anagnostou","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B41","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1542\/peds.2018-0516B","article-title":"Shared decision-making in pediatric practice: a broad view","volume":"142","author":"Kon","year":"2018","journal-title":"Pediatrics"},{"key":"B42","doi-asserted-by":"crossref","first-page":"S142","DOI":"10.1542\/peds.2018-0516D","article-title":"Involving youth with a chronic illness in decision-making: highlighting the role of providers","volume":"142","author":"Miller","year":"2018","journal-title":"Pediatrics"},{"key":"B43","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.anai.2020.05.031","article-title":"Shared decision-making in the care of a patient with food allergy","volume":"125","author":"Greenhawt","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B44","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.anai.2020.01.016","article-title":"Unmet needs of children with peanut allergy: aligning the risks and the evidence","volume":"124","author":"Chan","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2020.01.030"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2021\/00000042\/00000002\/art00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T23:56:40Z","timestamp":1615247800000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2021.42.200107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,1]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3,1]]}},"alternative-id":["1088-5412(20210301)42:2L.118;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2021.42.200107","relation":{},"ISSN":["1088-5412"],"issn-type":[{"value":"1088-5412","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3,1]]}}}